glp-1 obesity drugs news today 2025 october 9 Poll: 1 in 8 Adults Say They Are Currently Taking Study finds GLP-1 receptor agonists

What are the safety issues with unapproved versions of GLP-1 agonists

This underscores why receiving glutathione IV under qualified medical supervision matters

These GLP-1s were injected right into the body, forgoing the digestive tract

The practical research implication is substantial: studies using ipamorelin to investigate GH/IGF-1 axis effects are not confounded by concurrent activation of the hypothalamic-pituitary-adrenal (HPA) axis a major experimental advantage over GHRP-2 and GHRP-6 in any protocol where cortisol or ACTH are outcome variables, or where HPA axis activation would represent an uncontrolled experimental variable